Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

Elias Jabbour, Deborah Thomas, Hagop Kantarjian, Lingsha Zhou, Sherry Pierce, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.

Original languageEnglish (US)
Pages (from-to)899-902
Number of pages4
JournalBlood
Volume118
Issue number4
DOIs
StatePublished - Jul 28 2011
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Thalidomide
Prednisone
Therapeutics
lenalidomide

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Jabbour, E., Thomas, D., Kantarjian, H., Zhou, L., Pierce, S., Cortes, J., & Verstovsek, S. (2011). Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood, 118(4), 899-902. https://doi.org/10.1182/blood-2010-12-325589

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. / Jabbour, Elias; Thomas, Deborah; Kantarjian, Hagop; Zhou, Lingsha; Pierce, Sherry; Cortes, Jorge; Verstovsek, Srdan.

In: Blood, Vol. 118, No. 4, 28.07.2011, p. 899-902.

Research output: Contribution to journalArticle

Jabbour, E, Thomas, D, Kantarjian, H, Zhou, L, Pierce, S, Cortes, J & Verstovsek, S 2011, 'Comparison of thalidomide and lenalidomide as therapy for myelofibrosis', Blood, vol. 118, no. 4, pp. 899-902. https://doi.org/10.1182/blood-2010-12-325589
Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28;118(4):899-902. https://doi.org/10.1182/blood-2010-12-325589
Jabbour, Elias ; Thomas, Deborah ; Kantarjian, Hagop ; Zhou, Lingsha ; Pierce, Sherry ; Cortes, Jorge ; Verstovsek, Srdan. / Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. In: Blood. 2011 ; Vol. 118, No. 4. pp. 899-902.
@article{c9fe4a34d1cb4f43a41ffbea6a7e69a8,
title = "Comparison of thalidomide and lenalidomide as therapy for myelofibrosis",
abstract = "With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34{\%}-38{\%}) than thalidomide (16{\%}; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13{\%}) because of side effects then patients on single-agents therapy (32{\%}-39{\%}). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.",
author = "Elias Jabbour and Deborah Thomas and Hagop Kantarjian and Lingsha Zhou and Sherry Pierce and Jorge Cortes and Srdan Verstovsek",
year = "2011",
month = "7",
day = "28",
doi = "10.1182/blood-2010-12-325589",
language = "English (US)",
volume = "118",
pages = "899--902",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

AU - Jabbour, Elias

AU - Thomas, Deborah

AU - Kantarjian, Hagop

AU - Zhou, Lingsha

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Verstovsek, Srdan

PY - 2011/7/28

Y1 - 2011/7/28

N2 - With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.

AB - With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we reassessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.

UR - http://www.scopus.com/inward/record.url?scp=79960999112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960999112&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-12-325589

DO - 10.1182/blood-2010-12-325589

M3 - Article

C2 - 21622644

AN - SCOPUS:79960999112

VL - 118

SP - 899

EP - 902

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -